Biosimilar competition: lessons from Europe | Zendy

Henry G. Grabowski | Zendy; Rahul Guha | Zendy; Maria Salgado | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Biosimilar competition: lessons from Europe

Author(s) -

Henry G. Grabowski,

Rahul Guha,

Maria Salgado

Publication year - 2014

Publication title -

nature reviews drug discovery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 9.921

H-Index - 328

eISSN - 1474-1784

pISSN - 1474-1776

DOI - 10.1038/nrd4210

Subject(s) - biosimilar , filgrastim , competition (biology) , european market , medicine , pharmacology , business , international trade , ecology , biology , chemotherapy , granulocyte colony stimulating factor

Since 2005, the European Union has had a regulatory pathway through which biosimilars are approved centrally by the European Medicines Agency (EMA), as with pioneer biologics. So far, biosimilars have been approved in four separate classes: somatropins, erythropoiesis-stimulating agents (ESAs), granulocyte colony-stimulating factors (G-CSFs) and, most recently, monoclonal antibodies that are specific for tum…

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research